Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

Chapman P. B.; Robert C.; Larkin J.; Haanen J. B.; Ribas A.; Hogg D.; Hamid O.; Ascierto P. A.; Testori A.; Lorigan P. C.; Dummer R.; Sosman J. A.; Flaherty K. T.; Chang I.; Coleman S.; Caro I.; Hauschild A.; McArthur G. A.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

【24h】

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

机译：vemurafenib在BRAF（V600）突变阳性转移性黑色素瘤中：随机的Brim-3研究的最终整体生存结果

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with BRAF(V600) mutation-positive metastatic melanoma. We present final OS data from BRIM-3.

机译：背景：Brim-3试验表明，与BRAF（V600）突变阳性转移性黑素瘤的治疗 - 天真患者的耐酸尿嘧啶相比，vemurafenib的无进展生存（PFS）和整体存活（OS）。我们从Brim-3呈现最终的OS数据。

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2017年第10期|共7页
作者
Chapman P. B.; Robert C.; Larkin J.; Haanen J. B.; Ribas A.; Hogg D.; Hamid O.; Ascierto P. A.; Testori A.; Lorigan P. C.; Dummer R.; Sosman J. A.; Flaherty K. T.; Chang I.; Coleman S.; Caro I.; Hauschild A.; McArthur G. A.;
展开▼
作者单位

Mem Sloan Kettering Canc Ctr Dept Med 1275 York Ave New York NY 10065 USA;

Inst Gustave Roussy Dept Med Paris France;

Royal Marsden NHS Fdn Trust Dept Med London England;

Netherlands Canc Inst Div Med Oncol Amsterdam Netherlands;

Univ Calif Los Angeles Jonsson Comprehens Canc Ctr Dept Med Hematol &

Oncol Los Angeles CA;

Princess Margaret Hosp Div Med Oncol &

Hematol Toronto ON Canada;

Angeles Clin &

Res Inst Melanoma Therapeut Los Angeles CA USA;

Fdn G Pascale Ist Nazl Tumori Melanoma Canc Immunotherapy &

Innovat Therapy Uni Naples Italy;

Ist Europeo Oncol Melanoma &

Sarcoma Milan Italy;

Univ Manchester Dept Med Oncol Manchester Lancs England;

Univ Zurich Dept Dermatol Zurich Switzerland;

Northwestern Univ Robert H Lurie Comprehens Canc Ctr Dept Hematol Oncol Chicago IL 60611 USA;

Massachusetts Gen Hosp Dept Med Boston MA 02114 USA;

Genentech Inc Dept Biostat Prod Dev Biometr San Francisco CA 94080 USA;

Genentech Inc Clin Dept San Francisco CA 94080 USA;

Genentech Inc Prod Dev Oncol San Francisco CA 94080 USA;

Univ Hosp Schleswig Holstein Dept Dermatol Kiel Germany;

Peter MacCallum Canc Ctr Dept Oncol East Melbourne Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
melanoma; BRAF mutation; vemurafenib; dacarbazine;

机译：黑色素瘤;BRAF突变;vemurafenib;达卡尔巴犬;

相似文献

外文文献
中文文献
专利

1. Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study [J] . Chapman P. B., Robert C., Larkin J., Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第10期

机译：vemurafenib在BRAF（V600）突变阳性转移性黑色素瘤中：随机的Brim-3研究的最终整体生存结果
2. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis [J] . Blank Christian U., Larkin James, Arance Ana M., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：3219例BRAF（V600）突变阳性转移性黑素瘤的vemurafenib的开放标签，vemurafenib的多期安全研究：2年后续数据和长期响应者分析
3. The European Medicines Agency review of vemurafenib (Zelboraf?) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use [J] . DaRochaDiasS., SalmonsonT., VanZwieten-BootB., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2013,第7期

机译：欧洲药品管理局对vemurafenib（Zelboraf？）用于治疗BRAF V600突变阳性，不可切除或转移性黑色素瘤成年患者的综述：人类用药品委员会的科学评估摘要
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Development of Nanoliposomes for the Treatment of Braf V600e Mutated Parent and Vemurafenib-Resistant Melanoma [D] . Fu, Yige. 2021

机译：用于治疗BRAF V600E突变父母和vemureafenib抗性黑素瘤的纳米脂质体的研制
6. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study [O] . P B Chapman, C Robert, J Larkin, -1

机译：维拉非尼在BRAFV600突变阳性转移性黑色素瘤患者中的作用：随机BRIM-3研究的最终总体生存结果
7. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study [O] . Chapman, P B, Robert, C, Larkin, J, 2017

机译：维拉非尼在BRAFV600突变阳性转移性黑色素瘤患者中的作用：随机BRIM-3研究的最终总体生存结果

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

摘要

著录项

相似文献

相关主题

期刊订阅